OBJECTIVES

This real-world study aimed to assess work-related patient-reported outcomes in patients with spondyloarthritis (SpA) treated with golimumab in daily clinical practice.

METHODS : This 12-month multicenter, non-interventional, prospective study included working adults with active axial SpA (axSpA) or psoriatic arthritis (PsA) treated with golimumab according to the approved product label. Work productivity and activity impairment (WPAI) data were prospectively collected using the specific health problem instrument, WPAI:SHP. Data from the first 60 patients who completed the 3-month post-baseline visit (or were prematurely withdrawn prior to 3 months) are presented.

RESULTS : Sixty patients (47% males; mean age: 44.8 years; axSpA: 56.7%; PsA: 43.3%; mean baseline DAS28-ESR: 4.0±1.2) were enrolled between 06-Apr-2017 and 27-Nov-2017 by 10 public/private sector hospitals and 3 private offices in Greece. One patient was withdrawn 12.1 weeks after enrollment, having discontinued golimumab due to lack of therapeutic response. Overall, 23% (14/60) of the patients were bio-experienced, and 31.7% (19/60) received concomitant conventional disease-modifying antirheumatic drugs during the study period. At baseline, 72.9% (43/59), 91.4% (53/58), 94.9% (56/59), and 96.7% (58/60) of the patients reported absenteeism, presenteeism, work productivity loss, and activity impairment due to SpA, respectively, while the respective rates at 3 months were 46.4% (26/56), 89.3% (50/56), 91.1% (51/56), and 88.3% (53/60). The WPAI:SHP domain scores significantly decreased from baseline at 3 months post-baseline by a median (IQR) of 5.7% (0.0-15.8), 40.0% (10.0-50.0), 38.1% (10.0-50.8), and 40.0% (10.0-50.0), respectively (p<0.001 for all).

CONCLUSIONS : In actively working patients with SpA treated with golimumab in real-life settings, significant improvements in all WPAI:SHP outcomes were noted as early as 3 months after treatment initiation. The final anlaysis shall provide valuable real-world evidence on the impact of golimumab on work productivity and activity impairment in patients with SpA after 6 and 12 months of treatment.